|
|
Article: New Safety Concerns Have Begun to Erode the Market Share of Drug-Eluting Stents.
- Article from:
- Business Wire
- Article date:
- May 24, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c57795) has announced the addition of Decision Resources Inc.'s new report: Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks? to their offering.
A few years after their introduction in 2002, drug-eluting stents had all but replaced bare-metal stents in the treatment of coronary heart disease, capturing up to 90% of the market. Physicians favoured the new stents primarily because of their ability to minimize the risk of restenosis associated with bare-metal stents. Recently, however, new safety concerns have begun to erode the market share of drug-eluting stents. The ...